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Abstract 
Heart failure (HF) is a syndrome characterized by high prevalence in society, frequent hospitalization, reduced quality of 
life and high mortality (overall, 50% of patients are dead at an interval of 4 years [1], annual mortality varying from 5% to 75%). 
Outcomes in heart failure are highly variable, prognosis of individual patients differs considerably and trial data, though valuable, 
does not often give an adequate direction. Taking into account the high prevalence of heart failure in society and its complexity 
physicians need a model to predict the risk of death, to estimate the survival of heart failure patients. A key element of interest in this 
area is the survival function, usually noted by S and defined as 
x T a e t H x T a e e t H t S
) ( 0
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Heart failure - Definition 
Heart failure is a syndrome in which structural or 
functional cardiac conditions impair heart’s ability to 
supply sufficient blood flow in order to meet the body's 
needs, or to do that at an elevated diastolic pressure [2]. 
There are many definitions of this complex 
syndrome, but none is satisfactory, due to the lack of a 
universally agreed definition and challenges in definitive 
diagnosis. Until now, only some selective features of this 
extremely complex physiological state were highlighted in 
the definitions – oxygen consumption, cardiac preload 
and afterload, left ventricular remodeling and dysfunction, 
ventricular filling pressures, neurohormonal responses, 
exercise capacity, etc.  
The new American and European guidelines and 
recommendations include new information and have the 
declared intention to simplify and clarify the previous 
recommendations [1]. 
Heart failure is a clinical syndrome in which 
patients have featured symptoms typical of heart failure 
(breathlessness at rest or on exercise, fatigue, tiredness, 
ankle swelling) and typical signs of heart failure 
(tachycardia, tachypnoea, pulmonary rales, pleural 
effusion, raised jugular venous pressure, peripheral 
oedema, hepatomegaly) and objective evidence of a 
structural or functional abnormality of the heart at rest 
(cardiomegaly, third heart sound, cardiac murmurs, 
abnormality on the echocardiogram, raised natriuretic 
peptide concentration) [1].  
A clinical response to a pharmacological therapy 
directed to heart failure is not sufficient for the diagnosis 
of heart failure, although the usefulness/efficacy of the 
treatment may be established by the improvement in 
symptoms or signs (e.g. diuretic administration) [3].  
Heart failure may be classified by structural 
abnormality (ACC/AHA), or by symptoms relating to 
functional capacity (NYHA). 
 
ACC/AHA stages of heart failure (based on 
structure and damage to heart muscle) [4] 
Stage A: At high risk for developing heart failure. 
No identified structural or functional abnormality; 
no signs or symptoms. 
Stage B: Developed structural heart disease that 
is strongly associated with the development of 
heart failure, but without signs or symptoms. 
Stage C: Symptomatic heart failure associated 
with underlying structural heart disease. 
Stage D: Advanced structural heart disease and 
marked symptoms of heart failure at rest despite 
maximal medical therapy. 
* NYHA classification refers to stages C and D Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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NYHA functional classification (severity based on 
symptoms and physical activity) [5] 
Class I: No limitation of physical activity. 
Ordinary physical activity does not cause fatigue, 
palpitation, or dyspnoea. 
Class II: Slight limitation of physical activity. 
Comfortable at rest, but ordinary physical activity 
results in fatigue, palpitation, or dyspnoea. 
Class III: Marked limitation of physical activity. 
Comfortable at rest, but less than ordinary 
activity results in fatigue, palpitation, or 
dyspnoea. 
Class IV: Unable to carry on any physical activity 
without discomfort. Symptoms at rest. If any 
physical activity is undertaken, discomfort is 
increased. 
Descriptive terms in heart failure 
Acute and chronic heart failure 
Acute heart failure (ICA) is a clinical syndrome 
caused by the action of a factor with brutal effect, often 
reversible, over the functional capacity of the heart. 
Acute heart failure is defined by the rapid onset 
of signs and symptoms (secondary to cardiac dysfunction) 
resulting from impaired heart.  It may occur in the 
presence or absence of preexisting heart disease. Acute 
heart failure may be an expression of systolic or diastolic 
dysfunction, heart rhythm abnormalities, or disturbances 
of preload or afterload. It is often a threat, life threatening, 
requiring emergency treatment. 
Acute heart failure may present as acute de 
novo heart failure (a patient without known preexisting 
heart disease) or acute decompensation of chronic heart 
failure. In  practice,  the most common form is 
decompensation of chronic heart failure. 
 
Classification of heart failure [1] 
● New onset                 First presentation,  
                                                    Acute or slow onset 
● Transient                   Recurrent or episodic 
● Chronic                      Persistent 
                                     Stable, worsening,  
                                                    or decompensated 
Other forms of acute heart failure (ICA) include: 
acute heart failure with hypertension, pulmonary edema, 
cardiogenic shock, heart failure with increased cardiac 
output and right heart failure. 
There is a number of well-known classifications 
that are used in the context of acute heart failure 
secondary to a myocardial infarction: Killip classification 
(designed to clinically assess the severity of myocardial 
dysfunction) [6] and Forrester classification (evaluate 
clinical and hemodynamic patients with acute myocardial 
infarction) [7]. In the original publication, [8] therapeutic 
strategy depended on clinical and hemodynamic status - 
Forrester classification. Patients are classified according 
to signs of peripheral hypoperfusion (weak pulse, moist 
skin, cold, peripheral cyanosis, hypotension, tachycardia, 
confusion, oliguria) and to signs of pulmonary congestion 
(rales, chest x-ray changes). The mortality rate is different 
according to the class, respectively 2.2% in Class I, 
10.1% in Class II, 22.4% Class III, to 55.5% in Class IV. 
Killip classification [6] 
Designed to provide a clinical estimate of the 
severity of circulatory derangement in the treatment of 
acute myocardial infarction. 
Stage I: No heart failure. No clinical signs of 
cardiac decompensation (PCWP—estimate of 
left atrial pressure) 
Stage II: Heart failure. Diagnostic criteria include 
rales, S3 gallop, and pulmonary venous 
hypertension. Pulmonary congestion with wet 
rales in the lower half of the lung fields.  
Stage III: Severe heart failure. Frank pulmonary 
oedema with rales throughout the lung fields 
Stage IV: Cardiogenic shock. Signs include 
hypotension (SBP b90 mmHg), and evidence of 
peripheral vasoconstriction such as oliguria, 
cyanosis and sweating 
Forrester classification [7] 
Designed to describe clinical and haemodynamic 
status in acute myocardial infarction. 
1. Normal perfusion and pulmonary wedge 
     pressure 
2.  Poor perfusion and low PCWP 
     (hypovolaemic) 
3.  Nearly normal perfusion and high PCWP 
     (pulmonary oedema) 
4.  Poor perfusion and high PCWP  
     (cardiogenic shock) 
Another classification of severity of acute heart 
failure, used in some intensive care and coronary units, 
has been validated for cardiomyopathy [9], based on 
clinical signs [10], applicable in case of chronic 
decompensated heart failure [9]. 
Patients are divided into 4 classes based on two 
clinical criteria: assessment of perfusion / peripheral 
circulation and skin appearance and pulmonary 
congestion (appreciated by auscultation).  
  Class I warm skin without rales, 
  Class II warm skin, rales present 
  Class III cold skin, without rales 
  Class IV cold skin, rales present 
This classification allows an accurate 
assessment of prognosis regarding the patients with 
cardiomyopathy [11]. 
Heart failure is a clinical and functional 
diagnosis, expression of supply / demand balance 
alteration; a relation in which both terms are equally 
important. A simple, objective, definition of chronic heart 
failure is difficult as long as there are no precise Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
  423 
© 2010, Carol Davila University Foundation
boundaries between ventricular and heart dysfunction 
(intracavitary pressure limit values, changes of flow, size 
and volume cavities) [3]. 
 
Diastolic versus systolic heart failure  
The cardiologist’s interest all over the world has 
been directed, for a long time, to the study of the systolic 
function of heart, being considered the key in the 
pathophysiology of heart failure. In the last decade, 
numerous studies have attempted to shed light on natural 
history, pathophysiology, diagnosis, prognosis and 
treatment of heart failure with diastolic dysfunction. 
Epidemiological and clinical studies applied on 
hospital populations revealed that a percentage of 30-
50% of patients with heart failure have preserved left 
ventricular function. Epidemiological data in patients with 
diastolic dysfunction are still very limited compared to 
available data on epidemiology of heart failure with 
systolic dysfunction, much more studied and well-
documented. 
Diastolic heart failure is characterized by 3 basic 
elements: the presence of signs and symptoms of heart 
failure, preserved left ventricular systolic function (ejection 
fraction>45%) and the presence of abnormal diastolic 
function (alterations of relaxation and / or compliance) 
[12]. 
We must make a clear delimitation between two 
different concepts: diastolic dysfunction and diastolic 
heart failure. Diastolic dysfunction characterized by 
abnormal mechanical properties and diastolic heart 
failure, is a clinical syndrome characterized by signs and 
symptoms of heart failure and evidence of altered 
diastolic function. 
The concept of diastolic dysfunction defined by 
the existence of an abnormality of one or both of the 
constituent processes of diastole: relaxation and 
compliance. They may suffer elongation, delays or they 
may be incomplete, changes that can be measured with 
Doppler echography or cardiac catheterization [13]. These 
abnormalities of diastolic function may be detected in the 
presence or absence of the clinical syndrome of diastolic 
heart failure; they can also be noticed alone or with 
concomitant abnormalities of systolic function [14, 15]. 
Population studies estimate that approximately 
5% of the general population have isolated diastolic 
dysfunction; systolic dysfunction has a similar rate, about 
half being asymptomatic [16]. 
The main etiology of heart failure in developed 
societies is ischemic heart disease. In this context, many 
signs of heart failure are associated with left ventricular 
systolic dysfunction, although diastolic impairment at rest 
is usually present [3]. 
Diastolic dysfunction in young patients is rare 
(about 15% in populations under 50 years), but it 
increases in importance in the elders (50% in patients 
over 70 years old) [17-22]. 
Diastolic dysfunction is more common in women 
in whose systolic hypertension and myocardial 
hypertrophy contribute to cardiac dysfunction [23, 24]. 
Although most patients with acute pulmonary 
edema have a systolic dysfunction, many cases of 
developing a clinical picture of acute pulmonary edema in 
patients with diastolic heart failure with preserved systolic 
function are described in literature [25]. 
Among the patients with chronic heart failure, a 
significant percentage  has diastolic heart failure with 
preserved systolic function, if we take into account left 
ventricular ejection fraction at rest [23, 26]. 
Diastolic and systolic heart failure cannot be 
considered as separate pathophysiological entities, they 
coexist in most patients with the dominance of one or the 
other [3]. Most patients with systolic dysfunction associate 
changes in diastolic function [3].  In some patients with 
hypertension or hypertrophic cardiomyopathy, the 
dominant opinion is that diastolic dysfunction and 
abnormalities of relaxation and compliance are rather an 
earlier and more sensitive marker of cardiac damage than 
the alteration of systolic function, measured by decreased 
ejection fraction [3, 23, 27]. 
 
Other descriptive terms in heart failure 
A number of other descriptive terms was 
frequently used in the past, but now they are used only 
occasionally, their clinical value being reduced. These 
terms do not provide information on the etiology and they 
have a reduced influence in establishing a modern heart 
failure therapy. 
The terms of right and left heart failure, forward 
and backward HF, high and low output HF, mild, 
moderate, or severe HF are old terms used somehow 
arbitrary, expressing an imprecise measure of this 
complex clinical syndrome. 
Currently, the assessment of dyspnea and the 
limitation of the daily work are done by classifying the 
patient in functional class NYHA-New York Heart 
Association and the decline of functional assessment is 
performed using the Katz ADL Scale-Activities of Daily 
Living [28]. 
Descriptive epidemiology 
The importance and extent of the problem.  
Incidence. Prevalence 
Heart failure is a clinical syndrome, which, 
epidemiologically, is in a continuous growth in the 
economic developed countries and the developing ones, 
in contrast to ischemic heart disease, which is declining in 
the developed countries, due to the prevention 
programs. This fact is due to an aging population and to 
significant advances in the diagnosis and pharmacological 
treatment of heart disease. 
Congestive heart failure (CHF) is a major public 
healthcare problem, being an invalidating condition, with a Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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bad long-term prognosis, which reduces the quality of life 
and has a considerable economic cost to the individual 
and the society in general. 
Current estimates show that CHF affects over 5 
million people in the U.S., approximately 2% of adults and 
10% of elderly people being affected by this 
“cardiovascular epidemic” which was designated as a 
national research priority [29]. 
With an incidence of over 400,000 new cases 
diagnosed each year [17], and approximately 1 million 
hospital admissions annually, out of which over 80%   
patients aged over 65 years [17, 30], heart failure is the 
only major cardiovascular disease that increases in the 
United States. 
Today it is estimated that the prevalence in the 
European countries ranges between 0.4 and 2% [31], the 
studies estimating that about 14 million of the 
approximately 900 million inhabitants of the 51 European 
countries suffer from heart failure. 
The prevalence of heart failure increases with 
age [32], the average age of this population being 74-75 
years old and it is due to increase in time, the data for the 
elderly population show an increased percentage of 
prevalence of disease [33-36]. 
The large number of studies carried out on a 
large amount of heart failure patients show the attention 
given to heart failure in clinical practice. We must note 
that most studies that refer to therapeutic management 
address to patients with heart failure and systolic 
dysfunction, fewer to patients with preserved systolic 
function and heart failure. 
In the last decade, special attention has been 
paid to diastolic heart failure [30], pathophysiological 
condition in which heart failure syndrome is caused by 
abnormalities of diastolic ventricular function.   
Epidemiological and clinical studies conducted on hospital 
populations revealed that a percentage of 30-50% of 
patients with CHF have preserved left ventricular function. 
Epidemiological data on diastolic dysfunction are still very 
limited compared to available data on epidemiology of 
heart failure with systolic dysfunction, carefully studied 
and well documented. 
Diastolic heart failure receives increasing interest 
from clinicians around the world because its clinical and 
epidemiological significance proved to be growing [37]. In 
the last decade, a series of data has been accumulated 
and it provides conclusive information on the 
epidemiology of diastolic dysfunction, about its magnitude 
and complexity. The studies performed in the recent years 
revealed an annual mortality rate of patients with 
preserved systolic function heart failure of 8-17% [38] and 
9-28% [39]. Although this is a significantly lower mortality 
rate than that of patients with heart failure and systolic 
dysfunction (about half), it represents 3-4 times the 
mortality of patients with the same age enrolled in the 
control group [39].  
 
Age and prevalence of heart failure  
As mentioned above the prevalence of heart 
failure increases with age [30], the average age of this 
population being 74-75 years old.  Because of the 
increasing proportion of elderly population, an increase in 
the prevalence of this disease is registered [33-36]. Data 
from literature show an increase in prevalence from 6.6% 
in 65-69 year-old group and to 14% in over 85 year-old 
group [29]. 
Looking at the percentage of patients with 
diastolic heart failure from the people with symptomatic 
CHF, we can notice a clear increase with age. Diastolic 
HF percentage varies from a rate of approximately 15% in 
populations under 50 years, to 33% in the 50-70 years 
age group and 50% in patients over 70 years [17, 18, 21, 
22, 40, 41]. 
Recent clinical studies in patients with CHF and 
population observations estimate that heart failure with 
preserved systolic function represents  approximately 30-
50% of cases hospitalized for symptomatic heart failure 
and more than 50% for people over 65 years [26, 42-44]. 
Increasing prevalence of diastolic dysfunction in 
the elderly people is due to: age related to physiological 
changes (increased interstitial fibrosis and myocardial 
hypertrophy, which causes alteration of ventricular 
relaxation and compliance) and induced 
pathophysiological changes associated comorbidities - 
essential hypertension (the most important factor), 
ischemic heart disease, diabetes and left ventricular 
hypertrophy. With aging, there is a higher prevalence of 
these factors, which may explain an increased percentage 
of patients with diastolic dysfunction in the elderly people 
[45]. The risk factors mentioned above determine 
structural and functional heart adaptations that, along with 
age-induced changes, lead to alterations in diastolic 
function. 
 
Sex, etiology and the prevalence of heart failure  
In younger age groups, patients under 50 years 
old, heart failure as a whole (patients with systolic 
dysfunction and diastolic dysfunction) is more common in 
men. At this age, the most common etiology is ischemic 
coronary disease, more common in males.  The main 
causes of heart failure are coronary heart disease (70% of 
patients with HF), valve disease and cardiomyopathies 
each with approximately 10% of cases. In elderly people, 
prevalence is equal between the sexes [1]. 
Numerous epidemiological reports have noticed 
that women with heart failure have an increased 
percentage (than men) of preserved systolic function [40, 
44, 46, 47]. 
In similar age groups and associated clinical 
conditions, female patients have more diastolic heart 
failure than men. Out of the 2.4 million female patients 
with heart failure in the U.S., more than 50% of them have 
a normal systolic function [40]. Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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There is no registry of heart failure in Romania 
as there is in other countries, so there is no precise data 
on the epidemiology of heart failure. Older data estimate a 
heart failure prevalence of 0.2-0.5% in the general 
population, that means approximately 150,000-200,000 
patients with heart failure diagnosis [48]. Recent data 
from Statistics by Country for congestive Heart Failure 
[49] estimate an incidence of 0.146% (32 875) cases of 
heart failure and a prevalence of 1.76% (394 509) cases 
of heart failure in Romania.  The President of the 
Romanian Heart Failure Working Group estimates the 
number of heart failure patients, at approximately 800-900 
000, a number that increases permanently [50]. 
 
Morbidity. Quality of life. Costs 
HF morbidity is particularly important; patients 
with heart failure require frequent medical visits at home 
or rehospitalization, which represents a significant 
expenditure of health resources. In the first year after 
hospital discharge, approximately 50% of patients with 
heart failure require rehospitalization, the data is similar in 
those with systolic dysfunction or diastolic dysfunction. 
Heart failure is the main cause of hospitalization 
in the Medicare population in the USA [51]. Data  from 
Scotland show that the number of hospitalizations in 
which heart failure is primary or secondary diagnosis of 
hospitalization is increasing in Europe. According to a 
hospital record, 4.7% of women admissions and 5.1% of 
men admissions are due to heart failure (at any time to 
diagnose it) [52]. While only a few cases are due to acute 
heart failure, at first presentation, most cases are due to 
decompensation of chronic heart failure. The HF incidence, 
regardless of the degree of severity, varies between 2.3 and 
3.7 per 1000 inhabitants per year [53-54]. 
Epidemiological data show that morbidity is 
decisively influenced by age, rehospitalization rate (at one 
year) increasing from 25% for under 50 year-old group, to 
50% for 50-70 year-old group [18].  
Some European studies show that about 1% of 
the national health budget is allocated to the therapy of 
heart failure; in the U.S., about 2% of the national health 
budget is allocated to this problem. The large number and 
the long period of hospitalization for acute heart failure or 
decompensation of chronic heart failure are a substantial 
economic burden for the healthcare budgets. In U.S., the 
first cause of hospitalization in patients over 65 years old 
is heart failure. In Scotland, the number of patients with 
heart failure in hospital increased with 60% between 1980 
and 1990. The United States spends about $ 20 billion 
annually, 10% of healthcare budget, allocated for the 
management of cardiovascular disease with heart failure, 
75% of the amount being allocated to hospital care. Heart 
failure is the most expensive cardiological syndrome 
[56,57]. 
 
Prognosis. Mortality  
Prognosis is heterogeneous and depends on the 
heart failure class, its etiology and the patient’s age. The 
prognosis of untreated heart failure is unknown. Multiple 
studies and metaanalyses highlighted various predictive 
criteria: clinical- radiological (NYHA functional class and 
heart size on chest x-ray examination), presence of atrial 
fibrillation, ejection fraction of VS, maximal O2 
consumption during exercise, 6-minute walk test, 
pulmonary capillary pressure, serum catecholamine, 
natriuretic peptides and ventricular arrhythmias. 
The latest ESC guidelines summarize the 
knowledge  about the conditions associated with a poor 
prognosis in heart failure: 
 
 
 
 
 
Demographics  Clinical  Electrophysiological  Functional/exertional  Laboratory  Imaging 
Advanced age * 
Ischaemic etiology 
* 
Resuscitated 
sudden death * 
Poor compliance 
Renal dysfunction 
Diabetes 
Anaemia 
COPD 
Depression 
Hypotension * 
NYHA functional 
class III–IV* 
Prior HF 
hospitalization * 
Tachycardia 
Pulmonary rales 
Aortic stenosis 
Low body mass 
index 
Sleep-related 
breathing 
disorders 
 
Tachycardia Q waves 
Wide QRS* 
LV hypertrophy 
 
Complex ventricular 
arrhythmias * 
Low heart rate variability 
Atrial fibrillation 
T-wave alternations 
 
Reduced work, low peak 
VO2 * 
Poor 6-minute walk 
distance 
High VE/VCO2 slope 
Periodic breathing 
 
 
Marked elevation 
of BNP/NT pro-
BNP* 
Hyponatraemia * 
Elevated troponin 
* 
Elevated 
biomarkers, 
neurohumoral 
activation * 
Elevated 
creatinine/BUN 
Elevated bilirubin 
Anaemia 
Elevated uric acid 
 
Low LVEF* 
Increased LV 
volumes 
Low cardiac index 
High LV filling 
pressure 
Restrictive mitral 
filling pattern, 
pulmonary 
hypertension 
Impaired right 
ventricular function 
* Powerful predictors. 
Table 1 Conditions associated with a poor prognosis in heart failure – according to ESC guidelines 2008 [1] Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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Framingham’s study reported a 65% survival 
rate at 1 year after specifying the diagnosis of heart 
failure, respectively 25% in men, and, 35-40% in women, 
meaning 5 years survival.  Another study - Mayo Clinic-
Minnesota, shows a similar 66% one-year survival after 
the diagnosis indication. The main causes of death are 
sudden death or terminal heart failure (50% of the 
cases). Depending on the functional NYHA class in which 
the patients are reported, different mortality rates are 
recorded: CONSENSUS I studies elderly patients with 
heart failure; NYHA class IV, reports a mortality rate of 
44% at 6 months, and the V-Heft and SOLVD study 
shows a mortality rate of 15-20% at 1 year, in patients in 
NYHA class II and III.  
Patients with acute heart failure have a very 
severe prognosis, large randomized trials with 
hospitalized patients for decompensated heart failure 
have shown a 9.6% mortality rate at 60 days and a 
35.2% combined mortality rate and rehospitalization at 60 
days [58, 59].  
Ischemic etiology proves to be a negative 
prognostic factor in AIRE and TRACE studies on patients 
with post-myocardial infarction heart failure, a 14-25% 
mortality rate in the 1 year registered in these patients. 
Mortality is particularly high in patients with acute 
myocardial infarction associated with severe HF, with a 
mortality rate close to 30% in the 1 year [59, 60]. 
Important observational studies that include 
patients with both systolic and diastolic heart failure show 
that although short-term mortality rate may be lower in 
patients with diastolic dysfunction, long-term survival 
analysis shows a similar mortality rate for both groups of 
patients, especially those over 65 years [14, 46]. Different 
results regarding mortality in diastolic heart failure may be 
explained by differences in etiology and age of the 
patients taken into survey. 
Another determinant of mortality is the age, 
mortality in diastolic heart failure increases significantly 
with age. The data show that mortality at 5 years is 15% 
in below the 50-year-old group, 33% in 50-70 year-old 
group, reaching 50% in patients over 70 years old. Thus, 
in the elderly people over 70 years old the mortality rate 
for heart failure diastolic and heart failure systolic is 
practically equivalent [15, 22, 46]. 
Patterns of morbidity and mortality in Romania 
have undergone significant changes in the recent 
decades, due to the increased incidence and prevalence 
of chronic disease and mortality associated with these 
causes, in the context of the increasing percentage of 
elderly population, coupled with the action of multiple 
biological, environmental, behavioral risk factors as well 
as the influence of the socio-economic conditions and 
healthcare. 
Compared to the average of the first 15 states 
included in the European Union (EU-15) and the average 
of the new member states (NMS-10), the overall mortality, 
has shown a slow downward trend (EU-15 average was 
9.93 deaths per 1000 inhabitants in 1999 and 9.67 deaths 
per 1000 inhabitants in 2001, and the NMS-10 average 
was 10.78 deaths per 1,000 inhabitants in 1999 and 10.36 
deaths per 1,000 inhabitants in 2002) [61].  Romania is 
recording a substantial increase in overall mortality rate, 
which, combined with the dynamics of birth and fertility 
leads to a long-term aging population process, with major 
negative consequences for both the healthcare system 
and the social security one.   
There are not sufficient epidemiological data yet  
on diastolic heart failure in Romania, some studies show 
a high mortality rate, at 1 year up to 29% in the diastolic 
heart failure lot and 33% in systolic (note patients 
included in the study are severe cases that required 
hospitalization in an emergency hospital) [62]. 
Prognosis of individual patients differs 
considerably, outcomes in highly variable trial data often 
do not give an adequate direction; taking into 
consideration the magnitude of this syndrome in the 
society and its complexity, we need a model to predict the 
risk of death, to estimate survival of heart failure patients.  
Survival analysis is a branch of statistics dealing 
with the life eextent of biological organisms. More 
generally, the survival analysis involves estimating the 
duration of survival until a certain event. In this context, in 
the specialized literature devoted to survival analysis, 
death is considered an “event”. Survival analysis seeks to 
answer the questions related to the survival of an 
individual or a lot from a population, over a certain period 
of time, and which are the causes of increase or decrease 
in the extent of survival. 
A key element in this area is the survival 
function, usually noted by S and defined as: 
S(t)=Pr(T>t)      ( 1 )  
in which  
-  t represents one moment in time; 
-  T is a random variable designating the time 
(or age) of death; 
-  Pr( ) notes the probability of occurrence of 
an event. 
Pr(T>t) means the probability that the time of 
death T occurs some time after the specified time, t. 
Usually, survival function S(t) has the following 
two properties: 
S(0)=1        ( 2 )  
S(t2) ≤ S(t1) for the moments of time   t2 > t1   (3) 
Property (3) shows that the survival function is 
monotonously decreasing in time. Survival at a later age 
is only possible if the subject has survived to all younger 
ages. 
Also, for the usual mathematical functions used 
for survival models, the value of S (t) function tends to 0 
(zero) at a time when t tends to infinity. Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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In connection with the survival function we can 
define the lifetime distribution function (life extension) 
by the relation: 
F(t) =Pr(T≤t) =1-S(t)     (4) 
Pr (T ≤ t) means the probability that death time T 
occurs before or at a specified time t, at the latest. 
Another extremely important concept is the 
hazard function, conventionally denoted by h (t). Hazard 
function can be defined in mathematical terms as in the 
relation (5): 
 
) (
) ( lim
) (
'
0 t S
t S
Δt
t) Δt|T t T P(t
t h
Δt
 
   


  (5) 
in which S’(t)  represents time derivative of 
survival function. 
Hazard function is the mortality rate at time t 
conditioned by survival until time t or later ( t T  ). 
Hazard function is non negative, this meaning 
that  0 ) (  t h . 
Survival models commonly use hazard function 
or hazard function logarithm. For example, a parametric 
model of the hazard function logarithm, based on a 
multiple linear distribution can be written as: 
in n i i i x a x a x a t h      ... ) ( log 2 2 1 1     (6) 
or, equivalently, 
... 11 22 ( ) exp( ... ) 11 22
ax ax a x n in ii ht a x a x ax e ii i n i n


  
     (7) 
In these equations the index i represents the 
number of observation, the index n is the number of 
independent variables noted xi1,  xi2,  …,  xin  and the a1, 
a2,…, an, are the coefficients of the model. In this relation 
α is a kind of reference function/value (baseline function), 
because    ) ( log t hi  when all independent variables 
are zero. The purpose of multiple regression is to highlight 
the relationship between a dependent variable and many 
independent variables (control variables, predictors). 
One of the most used functions of survival is the 
Cox multiple regression model [2], proportional hazards 
model. 
In Cox’s survival model  
) ( log ) ( 0 t h t             (8) 
In this case we have: 
 
in n i i i x a x a x a t h t h      ... ) ( log ) ( log 2 2 1 1 0      (9) 
or  
 
in n i i
i x a x a x a
t h
t h
    ...
) (
) (
log 2 2 1 1
0
   (10) 
which will result in a hazard function: 
in n i i x a x a x a
i e t h t h
   
...
0
2 2 1 1 ) ( ) (     (11)   
) ( 0 t h  is called baseline hazard function. In Cox’s model 
it is unspecified. 
Taking two observations, i and j in equation (11), 
the following formula results 
jn n ji j
in n i i
jn n ji j
in n i i
x a x a x a
x a x a x a
x a x a x a
x a x a x a
j
i
e
e
e t h
e t h
t h
t h
  
  
  
  
  ...
...
...
0
...
0
2 2 1 1
2 2 1 1
2 2 1 1
2 2 1 1
) (
) (
) (
) (
 (12)  
Since hazard functions as hazard ratio for any 
pair of observations, according to (12), it does not depend 
on time t, Cox’s model is often referred to as proportional 
hazards model.  
Cox’s model can be actually extended to include 
time-dependent variable x. In this case, however, Cox’s 
model is no longer a proportional hazards model. In this 
paper as in the vast majority of used applications, Cox’s 
model is used for variable x independent of time. The 
equation (11) can be written in the general form: 
x T a e t h t h ) ( ) ( 0  ,     ( 1 3 )  
in which a is n-dimensional column’s vector of 
model parameters, with components a1, a2,…, an, x is n-
dimensional column’s vector of independent variables 
with components x1  x2, …, xn , and T designates the sign 
of transposition of a vector. 
Survival function for Cox’s proportional hazards 
model (12) is 
x T a e t H x T a e e t H t S
) ( 0
0 ) ) ( exp( ) (
     (14) 
In which: 
dz z h t H
t
 
0
0 0 ) ( ) (      ( 1 5 )  
 
is cumulative hazard function. 
For baseline hazard function  ) ( 0 t h respectively 
for  ) ( 0 t H we can determine the values on experimental 
bases or we may use known statistical models: 
exponential, Weibull or Gompertz [64]. 
To determine the major factors that allow the   
forecasting survival (or mortality) we may use Cox’s 
multiple regression model, the proportional hazards model 
[63]. 
The next step is to fit the requested regression 
model to all data and to create a heart failure prognostic 
model.  
The number of individuals living with heart failure 
is steadily increasing and there are many applications of 
such a model that may estimate the survival of a patient 
with heart failure. 
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